ProCE Banner Activity

S1106: R-Bendamustine vs R-HyperCVAD Induction Therapy Followed by ASCT in MCL

Slideset Download
Conference Coverage
In this phase II trial, R-bendamustine induction showed similar response rates, 2-year PFS, and 2-year OS with less hematologic and marrow toxicity vs R-hyperCVAD.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen